Copyright © 2011 Khaleel M. Jamil and Salim I. Khakoo. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. A. Horowitz, R. H. Behrens, L. Okell, A. R. Fooks, and E. M. Riley, “NK cells as effectors of acquired immune responses: effector CD4⁺ T cell-dependent activation of NK cells following vaccination,” Journal of Immunology, vol. 185, no. 5, pp. 2808–2818, 2010. View at Publisher · View at Google Scholar · View at PubMed
2. A. De Maria, M. Fogli, S. Mazza et al., “Increased natural cytotoxicity receptor expression and relevant IL-10 production in NK cells from chronically infected viremic HCV patients,” European Journal of Immunology, vol. 37, no. 2, pp. 445–455, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
3. A. Moretta, G. Tambussi, C. Bottino et al., “A novel surface antigen expressed by a subset of human CD3^-CD16⁺ natural killer cells. Role in cell activation and regulation of cytolytic function,” Journal of Experimental Medicine, vol. 171, no. 3, pp. 695–714, 1990. View at Scopus
4. H. G. Ljunggren and K. Karre, “In search of the 'missing self': MHC molecules and NK cell recognition,” Immunology Today, vol. 11, no. 7, pp. 237–244, 1990. View at Scopus
5. P. Parham, “MHC class I molecules and KIRS in human history, health and survival,” Nature Reviews Immunology, vol. 5, no. 3, pp. 201–214, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
6. V. M. Braud, D. S. J. Allan, C. A. O'Callaghan et al., “HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C,” Nature, vol. 391, no. 6669, pp. 795–799, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
7. H. G. Shilling, L. A. Guethlein, N. W. Cheng et al., “Allelic polymorphism synergizes with variable gene content to individualize human KIR genotype,” Journal of Immunology, vol. 168, no. 5, pp. 2307–2315, 2002. View at Scopus
8. M. Yawata, N. Yawata, M. Draghi, F. Partheniou, A. M. Little, and P. Parham, “MHC class I specific inhibitory receptors and their ligands structure diverse human NK-cell repertoires toward a balance of missing self-response,” Blood, vol. 112, no. 6, pp. 2369–2380, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
9. H. Wende, M. Colonna, A. Ziegler, and A. Volz, “Organization of the leukocyte receptor cluster (LRC) on human Chromosome 19q13.4,” Mammalian Genome, vol. 10, no. 2, pp. 154–160, 1999. View at Publisher · View at Google Scholar · View at Scopus
10. R. J. Boyton and D. M. Altmann, “Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease,” Clinical and Experimental Immunology, vol. 149, no. 1, pp. 1–8, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
11. S. I. Khakoo and M. Carrington, “KIR and disease: a model system or system of models?” Immunological Reviews, vol. 214, no. 1, pp. 186–201, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
12. F. Canavez, N. T. Young, L. A. Guethlein et al., “Comparison of chimpanzee and human leukocyte Ig-like receptor genes reveals framework and rapidly evolving genes,” Journal of Immunology, vol. 167, no. 10, pp. 5786–5794, 2001. View at Scopus
13. P. Parham, L. Abi-Rached, L. Matevosyan et al., “Primate-specific regulation of natural killer cells,” Journal of Medical Primatology, vol. 39, no. 4, pp. 194–212, 2010. View at Publisher · View at Google Scholar · View at PubMed
14. S. G. E. Marsh, P. Parham, B. Dupont et al., “Killer-cell immunoglobulin-like receptor (KIR) nomenclature report, 2002,” Human Immunology, vol. 64, no. 6, pp. 648–654, 2003.
15. S. E. Hiby, J. J. Walker, K. M. O'Shaughnessy et al., “Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success,” Journal of Experimental Medicine, vol. 200, no. 8, pp. 957–965, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
16. S. E. Hiby, M. Ashrafian-Bonab, L. Farrell et al., “Distribution of killer cell immunoglobulin-like receptors (KIR) and their HLA-C ligands in two Iranian populations,” Immunogenetics, vol. 62, no. 2, pp. 65–73, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
17. S. E. Hiby, R. Apps, A. M. Sharkey et al., “Maternal activating KIRs protect against human reproductive failure mediated by fetal HLA-C2,” Journal of Clinical Investigation, vol. 120, no. 11, pp. 4102–4110, 2010. View at Publisher · View at Google Scholar · View at PubMed
18. Z. Lu, B. Zhang, S. Chen et al., “Association of KIR genotypes and haplotypes with susceptibility to chronic hepatitis B virus infection in Chinese Han population,” Cellular & Molecular Immunology, vol. 5, no. 6, pp. 457–463, 2008. View at Scopus
19. K. Cheent and S. I. Khakoo, “Natural killer cells: integrating diversity with function,” Immunology, vol. 126, no. 4, pp. 449–457, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
20. A. Kikuchi-Maki, T. L. Catina, and K. S. Campbell, “Cutting edge: KIR2DL4 transduces signals into human NK cells through association with the Fc receptor γ protein,” Journal of Immunology, vol. 174, no. 7, pp. 3859–3863, 2005.
21. S. I. Khakoo, R. Rajalingam, B. P. Shum et al., “Rapid evolution of NK cell receptor systems demonstrated by comparison of chimpanzees and humans,” Immunity, vol. 12, no. 6, pp. 687–698, 2000. View at Scopus
22. M. Colonna, G. Borsellino, M. Falco, G. B. Ferrara, and J. L. Strominger, “HLA-C is the inhibitory ligand that determines dominant resistance to lysis by NK1- and NK2-specific natural killer cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 24, pp. 12000–12004, 1993. View at Publisher · View at Google Scholar · View at Scopus
23. N. Wagtmann, S. Rajagopalan, C. C. Winter, M. Peruzzi, and E. O. Long, “Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer,” Immunity, vol. 3, no. 6, pp. 801–809, 1995. View at Publisher · View at Google Scholar · View at Scopus
24. A. K. Moesta, P. J. Norman, M. Yawata, N. Yawata, M. Gleimer, and P. Parham, “Synergistic polymorphism at two positions distal to the ligand-binding site makes KIR2DL2 a stronger receptor for HLA-C Than KIR2DL3,” Journal of Immunology, vol. 180, no. 6, pp. 3969–3979, 2008. View at Scopus
25. C. C. Winter, J. E. Gumperz, P. Parham, E. O. Long, and N. Wagtmann, “Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition,” Journal of Immunology, vol. 161, no. 2, pp. 571–577, 1998.
26. J. E. Gumperz, V. Litwin, J. H. Phillips, L. L. Lanier, and P. Parham, “The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor,” Journal of Experimental Medicine, vol. 181, no. 3, pp. 1133–1144, 1995. View at Publisher · View at Google Scholar · View at Scopus
27. D. Pende, R. Biassoni, C. Cantoni et al., “The natural killer cell receptor specific for HLA-A allotypes: a novel member of the p58/p70 family of inhibitory receptors that is characterized by three immunoglobulin-like domains and is expressed as a 140-kD disulphide- linked dimer,” Journal of Experimental Medicine, vol. 184, no. 2, pp. 505–518, 1996. View at Scopus
28. C. A. Stewart, F. Laugier-Anfossi, F. Vély et al., “Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 37, pp. 13224–13229, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
29. A. K. Moesta, T. Graef, L. Abi-Rached, A. M. O. Aguilar, L. A. Guethlein, and P. Parham, “Humans differ from other hominids in lacking an activating NK cell receptor that recognizes the C1 epitope of MHC class I,” Journal of Immunology, vol. 185, no. 7, pp. 4233–4237, 2010. View at Publisher · View at Google Scholar · View at PubMed
30. D. H. Raulet and R. E. Vance, “Self-tolerance of natural killer cells,” Nature Reviews Immunology, vol. 6, no. 7, pp. 520–531, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
31. S. Kim, J. Poursine-Laurent, S. M. Truscott et al., “Licensing of natural killer cells by host major histocompatibility complex class I molecules,” Nature, vol. 436, no. 7051, pp. 709–713, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
32. H. R. MacDonald, “NK cell tolerance: revisiting the central dogma,” Nature Immunology, vol. 6, no. 9, pp. 868–869, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
33. G. Alter, et al., “Reduced frequencies of NKp30+NKp46+, CD161+ and NKG2D+ NK cells in acute HCV infection may predict viral clearance,” Journal of Hepatology, 2010. In press.
34. B. Amadei, S. Urbani, A. Cazaly et al., “Activation of natural killer cells during acute infection with hepatitis C virus,” Gastroenterology, vol. 138, no. 4, pp. 1536–1545, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
35. S. Pelletier, C. Drouin, N. Bédard, S. I. Khakoo, J. Bruneau, and N. H. Shoukry, “Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses,” Journal of Hepatology, vol. 53, no. 5, pp. 805–816, 2010. View at Publisher · View at Google Scholar · View at PubMed
36. C. Morishima, D. M. Paschal, C. C. Wang et al., “Decreased NK cell frequency in chronic hepatitis C does not affect ex vivo cytolytic killing,” Hepatology, vol. 43, no. 3, pp. 573–580, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
37. J. Corado, F. Toro, H. Rivera, N. E. Bianco, L. Deibis, and J. B. De Sanctis, “Impairment of natural killer (NK) cytotoxic activity in hepatitis C virus (HCV) infection,” Clinical and Experimental Immunology, vol. 109, no. 3, pp. 451–457, 1997.
38. G. Pár, D. Rukavina, E. R. Podack et al., “Decrease in CD3-negative-CD8dim⁺ and Vδ2/Vγ9 TcR + peripheral blood lymphocyte counts, low perforin expression and the impairment of natural killer cell activity is associated with chronic hepatitis C virus infection,” Journal of Hepatology, vol. 37, no. 4, pp. 514–522, 2002. View at Publisher · View at Google Scholar · View at Scopus
39. M. S. Bonavita, A. Franco, M. Paroli et al., “Normalization of depressed natural killer activity after interferon-α therapy is associated with a low frequency of relapse in patients with chronic hepatitis C,” International Journal of Tissue Reactions, vol. 15, no. 1, pp. 11–16, 1993.
40. S. I. Khakoo, C. L. Thio, M. P. Martin et al., “HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection,” Science, vol. 305, no. 5685, pp. 872–874, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
41. V. Romero, J. Azocar, J. Zúñiga et al., “Interaction of NK inhibitory receptor genes with HLA-C and MHC class II alleles in Hepatitis C virus infection outcome,” Molecular Immunology, vol. 45, no. 9, pp. 2429–2436, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
42. L. Fadda, G. Borhis, P. Ahmed et al., “Peptide antagonism as a mechanism for NK cell activation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 22, pp. 10160–10165, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
43. G. Ahlenstiel, M. P. Martin, X. Gao, M. Carrington, and B. Rehermann, “Distinct KIR/HLA compound genotypes affect the kinetics of human antiviral natural killer cell responses,” Journal of Clinical Investigation, vol. 118, no. 3, pp. 1017–1026, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
44. S. Knapp, U. Warshow, D. Hegazy et al., “Consistent beneficial effects of killer cell immunoglobulin-like receptor 2dl3 and group 1 human leukocyte antigen-c following exposure to hepatitis c virus,” Hepatology, vol. 51, no. 4, pp. 1168–1175, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
45. J. R. Vidal-Castiñeira, A. López-Vázquez, R. Díaz-Peña et al., “Effect of killer immunoglobulin-like receptors in the response to combined treatment in patients with chronic hepatitis C virus infection,” Journal of Virology, vol. 84, no. 1, pp. 475–481, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
46. A. López-Vázquez, L. Rodrigo, J. Martínez-Borra et al., “Protective effect of the HLA-Bw4I80 epitope and the killer cell immunoglobulin-like receptor 3DS1 gene against the development of hepatocellular carcinoma in patients with hepatitis C virus infection,” Journal of Infectious Diseases, vol. 192, no. 1, pp. 162–165, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
47. J. Zúñiga, V. Romero, J. Azocar et al., “Protective KIR-HLA interactions for HCV infection in intravenous drug users,” Molecular Immunology, vol. 46, no. 13, pp. 2723–2727, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
48. V. L. Carneiro, D. C. Lemaire, M. T. Bendicho et al., “Natural killer cell receptor and HLA-C gene polymorphisms among patients with hepatitis C: a comparison between sustained virological responders and non-responders,” Liver International, vol. 30, no. 4, pp. 567–573, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
49. A. Rauch, R. Laird, E. McKinnon et al., “Influence of inhibitory killer immunoglobulin-like receptors and their HLA-C ligands on resolving hepatitis C virus infection,” Tissue Antigens, vol. 69, no. 1, pp. 237–240, 2007. View at Publisher · View at Google Scholar · View at Scopus
50. B. Oliviero, S. Varchetta, E. Paudice et al., “Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections,” Gastroenterology, vol. 137, no. 3, pp. 1151–1160.e7, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
51. R. J. Harrison, A. Ettorre, A.-M. Little, and S. I. Khakoo, “Association of NKG2A with treatment for chronic hepatitis C virus infection,” Clinical and Experimental Immunology, vol. 161, no. 2, pp. 306–314, 2010. View at Publisher · View at Google Scholar · View at PubMed
52. G. Ahlenstiel, R. H. Titerence, C. Koh et al., “Natural killer cells are polarized toward cytotoxicity in chronic hepatitis C in an interferon-alfa-dependent manner,” Gastroenterology, vol. 138, no. 1, pp. 325–335.e2, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
53. World Health Organization, “Fact Sheet 204,” 2008, http://www.who.int/mediacentre/factsheets/fs204/en/.
54. B. Custer, S. D. Sullivan, T. K. Hazlet, U. Iloeje, D. L. Veenstra, and K. V. Kowdley, “Global epidemiology of hepatitis B virus,” Journal of clinical gastroenterology, vol. 38, no. 10, pp. S158–S168, 2004. View at Scopus
55. X. Gao, Y. Jiao, L. Wang et al., “Inhibitory KIR and specific HLA-C gene combinations confer susceptibility to or protection against chronic hepatitis B,” Clinical Immunology, vol. 137, no. 1, pp. 139–146, 2010. View at Publisher · View at Google Scholar · View at PubMed
56. M. P. Martin, X. Gao, J. H. Lee et al., “Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS,” Nature Genetics, vol. 31, no. 4, pp. 429–434, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
57. Y. Qi, M. P. Martin, X. Gao et al., “KIR/HLA pleiotropism: protection against both HIV and opportunistic infections.,” PLoS Pathogens, vol. 2, no. 8, article e79, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
58. J. D. Barbour, U. Sriram, S. J. Caillier, J. A. Levy, F. M. Hecht, and J. R. Oksenberg, “Synergy or independence? Deciphering the interaction of HLA Class I and NK cell KIR alleles in early HIV-1 disease progression.,” PLoS pathogens, vol. 3, no. 4, article e43, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
59. G. B. Cohen, R. T. Gandhi, D. M. Davis et al., “The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells,” Immunity, vol. 10, no. 6, pp. 661–671, 1999. View at Publisher · View at Google Scholar · View at Scopus
60. R. Biassoni, A. Pessino, A. Malaspina et al., “Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules,” European Journal of Immunology, vol. 27, no. 12, pp. 3095–3099, 1997. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
61. G. Katz, G. Markel, S. Mizrahi, T. I. Arnon, and O. Mandelboim, “Recognition of HLA-Cw4 but not HLA-Cw6 by the NK cell receptor killer cell Ig-like receptor two-domain short tail number 4,” Journal of Immunology, vol. 166, no. 12, pp. 7260–7267, 2001. View at Scopus
62. M. S. Malnati, M. Peruzzi, K. C. Parker et al., “Peptide specificity in the recognition of MHC class I by natural killer cell clones,” Science, vol. 267, no. 5200, pp. 1016–1018, 1995. View at Scopus
63. S. Gaudieri, D. DeSantis, E. McKinnon et al., “Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression,” Genes and Immunity, vol. 6, no. 8, pp. 683–690, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
64. S. Boulet, S. Sharafi, N. Simic et al., “Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals,” AIDS, vol. 22, no. 5, pp. 595–599, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
65. G. Alter, M. P. Martin, N. Teigen et al., “Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes,” Journal of Experimental Medicine, vol. 204, no. 12, pp. 3027–3036, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
66. B. R. Long, L. C. Ndhlovu, J. R. Oksenberg et al., “Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection,” Journal of Virology, vol. 82, no. 10, pp. 4785–4792, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
67. R. Thomas, E. Yamada, G. Alter et al., “Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?” Journal of Immunology, vol. 180, no. 10, pp. 6743–6750, 2008. View at Scopus
68. M. P. Martin, Y. Qi, X. Gao et al., “Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1,” Nature Genetics, vol. 39, no. 6, pp. 733–740, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
69. G. M. O'Connor, K. J. Guinan, R. T. Cunningham, D. Middleton, P. Parham, and C. M. Gardiner, “Functional polymorphism of the KIR3DL1/S1 receptor on human NK cells,” Journal of Immunology, vol. 178, no. 1, pp. 235–241, 2007. View at Scopus
70. S. Rajagopalan, Y. T. Bryceson, S. P. Kuppusamy et al., “Activation of NK cells by an endocytosed receptor for soluble HLA-G,” PLoS Biology, vol. 4, no. 1, article no. e9, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
71. S. Boulet, R. Song, P. Kamya et al., “HIV protective KIR3DL1 and HLA-B genotypes influence NK cell function following stimulation with HLA-devoid cells,” Journal of Immunology, vol. 184, no. 4, pp. 2057–2064, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
72. J. Fellay, K. V. Shianna, D. Ge et al., “A whole-genome association study of major determinants for host control of HIV-1,” Science, vol. 317, no. 5840, pp. 944–947, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
73. F. Pereyra, X. Jia, P. J. McLaren, A. Telenti, P. I. W. De Bakker, and B. D. Walker, “The major genetic determinants of HIV-1 control affect HLA class I peptide presentation,” Science, vol. 330, no. 6010, pp. 1551–1557, 2010. View at Publisher · View at Google Scholar · View at PubMed
74. A. T. Makadzange, G. Gillespie, T. Dong et al., “Characterization of an HLA-C-restricted CTL response in chronic HIV infection,” European Journal of Immunology, vol. 40, no. 4, pp. 1036–1041, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
75. W. Jennes, S. Verheyden, C. Demanet et al., “Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands,” Journal of Immunology, vol. 177, no. 10, pp. 6588–6592, 2006. View at Scopus
76. R. Thomas, R. Apps, Y. Qi et al., “HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C,” Nature Genetics, vol. 41, no. 12, pp. 1290–1294, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
77. C. A. Biron, K. S. Byron, and J. L. Sullivan, “Severe herpesvirus infections in an adolescent without natural killer cells,” New England Journal of Medicine, vol. 320, no. 26, pp. 1731–1735, 1989. View at Scopus
78. M. Cook, D. Briggs, C. Craddock et al., “Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation,” Blood, vol. 107, no. 3, pp. 1230–1232, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
79. C. Chen, M. Busson, V. Rocha et al., “Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders,” Bone Marrow Transplantation, vol. 38, no. 6, pp. 437–444, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
80. J. A. Zaia, J. Y. Sun, G. M. Gallez-Hawkins et al., “The effect of single and combined activating killer immunoglobulin-like receptor genotypes on cytomegalovirus infection and immunity after hematopoietic cell transplantation,” Biology of Blood and Marrow Transplantation, vol. 15, no. 3, pp. 315–325, 2009. View at Publisher · View at Google Scholar · View at PubMed
81. V. R. Bonagura, Z. Du, E. Ashouri et al., “Activating killer cell immunoglobulin-like receptors 3DS1 and 2DS1 protect against developing the severe form of recurrent respiratory papillomatosis,” Human Immunology, vol. 71, no. 2, pp. 212–219, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
82. M. Carrington, S. Wang, M. P. Martin et al., “Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci,” Journal of Experimental Medicine, vol. 201, no. 7, pp. 1069–1075, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
83. E. Estefanía, N. Gómez-Lozano, F. Portero et al., “Influence of KIR gene diversity on the course of HSV-1 infection: resistance to the disease is associated with the absence of KIR2DL2 and KIR2DS2,” Tissue Antigens, vol. 70, no. 1, pp. 34–41, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
84. D. S. Korbel, O. C. Finney, and E. M. Riley, “Natural killer cells and innate immunity to protozoan pathogens,” International Journal for Parasitology, vol. 34, no. 13-14, pp. 1517–1528, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
85. K. Artavanis-Tsakonas, K. Eleme, K. L. McQueen et al., “Activation of a subset of human NK cells upon contact with Plasmodium falciparum-infected erythrocytes,” Journal of Immunology, vol. 171, no. 10, pp. 5396–5405, 2003. View at Scopus
86. M. Baratin, S. Roetynck, B. Pouvelle et al., “Dissection of the role of PfEMP1 and ICAM-1 in the sensing of Plasmodium falciparum-infected erythrocytes by natural killer cells,” PLoS One, vol. 2, no. 2, article no. e228, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus